+357 96 030922
info@marketpublishers.com

NSCLC: Update Bulletin [April 2016]

https://marketpublishers.com/r/N513C598273EN.html
Date: March 2016
Pages: 0
Price: US$ 995.00 (Single User License)
ID: N513C598273EN

Abstracts

Gain new KOL insights on the latest events with the potential to shape the targeted treatment of Non-Small Cell Lung Cancer (NSCLC). Topics covered include opinions about the FDA advisory committee vote against approval of Clovis's EGFR inhibitor rociletinib, the US FDA priority review granted for Roche's PD-L1 inhibitor atezolizumab for the treatment of locally advanced or metastatic NSCLC expressing PD-L1, the EMA's CHMP recommendation for approval of BMS's Opdivo (nivolumab) for the treatment of locally advanced or metastatic NSCLC after prior chemotherapy, OSE Pharma's Phase III trial of its OSE 2101 vaccine for the second- or third-line treatment of advanced HLA-A2 positive NSCLC, the US FDA and EU approval Boehringer Ingelheim's afatinib (Gilotrif /Giotrif) for the treatment of advanced squamous NSCLC that has progressed on or after platinum-based chemotherapy, and Ariad's initiation of Phase III development of its ALK inhibitor brigatinib.

What factors were primarily responsible for the negative FDA review for Clovis's rociletinib, and what lessons can be learned?

How do KOLs view the likely outcome of the TIGER-3 trial of Clovis' rociletinib?

Assuming Clovis' rociletinib finally gains approval, how successful will it be in competing with Tagrisso (osimertinib; AstraZeneca)?

How do KOLs view Roche's anti- PD-L1 monoclonal antibody, atezolizumab, compared with BMS' Opdivo (nivolumab) and Merck & Co.'s Keytruda (pembrolizumab)?

How do KOLs rate PD-L1 as a biomarker to guide the treatment of NSCLC with Roche's atezolizumab?

+357 96 030922
info@marketpublishers.com

How do KOLs interpret the recent broadening of Opdivo’s indication in the EU?

How will the widening of the US and EU indication for Giotrif/Gilotrif (afatanib; Boehringer Ingelheim) impact its use?

What expectations do KOLs hold for OSE Pharma’s OSE 2101 as a potential NSCLC treatment?

How do KOLs rate Ariad’s brigatinib as a potential treatment for ALK-positive NSCLC?

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: NSCLC: Update Bulletin [April 2016]

Product link: https://marketpublishers.com/r/N513C598273EN.html

Price: US$ 995.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/N513C598273EN.html